Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pharmacyte Biotech Inc
(NQ:
PMCB
)
1.960
-0.120 (-5.77%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pharmacyte Biotech Inc
< Previous
1
2
Next >
PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay
December 08, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
November 30, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation
November 12, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA
September 27, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests
September 21, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA
September 16, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study
August 31, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise
August 25, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
August 23, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
August 19, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus
August 16, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Closing of $15-Million Public Offering
August 12, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering
August 09, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering
August 02, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Update on Study Progress and Uplist to Nasdaq
July 14, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Stability Test Results on Cells from Master Cell Bank
July 13, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Stability Test Results on Cells from Master Cell Bank
July 12, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Reverse Stock Split
July 09, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Results of Vote at Annual Meeting of Stockholders
July 08, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Provides Update on Status of Activities to Lift Clinical Hold
June 24, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Shareholders Vote to Increase the Authorized Capital
June 22, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Adjournment of Annual Meeting of Stockholders, Recording of Stockholder Meeting Available
June 18, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Details to Attend This Week’s Virtual Annual Meeting of Shareholders
June 14, 2021
From
PharmaCyte Biotech, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.